Public sector hospitals in India face a critical shortage of Desferal, a vital iron chelator, endangering thalassemia patients who cannot afford its high cost. India Today.

Novartis has assured that steps are being taken to ensure the adequate supply of Desferal, a drug crucial for treating iron overload in Thalassemia patients. The drug is manufactured exclusively ...

DESFERAL® (deferoxamine) is an injectable medicine indicated for the treatment of iron overload, which may occur for example following blood transfusions necessary for the treatment of beta ...

Delhi thalassemia patients face a dire shortage of the essential injection Desferal, causing panic and desperation as alternatives fail to suffice. Explore. Search Wednesday, Jun 11, 2025.

MITEM PHARMA Acquires Worldwide Rights to DESFERAL® (deferoxamine) With the Backing of TECHLIFE CAPITAL and MACSF. September 25, 2024 02:13 AM Eastern Daylight Time.

Novartis, however, denied any current shortage. “Currently, there is no shortage of Desferal in Delhi or elsewhere in India,” a spokesperson told Business Today.

MASSY, France, September 25, 2024--MITEM PHARMA, the pharmaceutical laboratory based in France and dedicated to Medicines of Major Therapeutic Interest (M.I.T.M.), is pleased to announce the ...